From Wikipedia, the free encyclopedia
Acazicolcept (ALPN-101) is an experimental dual
CD28/
ICOS antagonist developed by
AbbVie.
[1]
[2]
[3]
References
-
^ Yang, Jing; Lickliter, Jason D.; Hillson, Jan L.; Means, Gary D.; Sanderson, Russell J.; Carley, Kay; Tercero, Almudena; Manjarrez, Kristi L.; Wiley, Jennifer R.; Peng, Stanford L. (July 2021).
"First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects". Clinical and Translational Science. 14 (4): 1314–1326.
doi:
10.1111/cts.12983.
PMC
8301585.
PMID
33503289.
-
^ Dillon, Stacey R.; Evans, Lawrence S.; Lewis, Katherine E.; Debrot, Susan; Blair, Tiffany C.; Mudri, Sherri; Kleist, Kayla; Levin, Steven D.; Bhandari, Janhavi G.; Garrett, Logan; Wolfson, Martin F.; Holland, Pamela M.; Rixon, Mark W.; Peng, Stanford L. (August 2023). "Non-Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept ( ALPN -101)". Arthritis & Rheumatology. 75 (8): 1344–1356.
doi:
10.1002/art.42484.
PMID
36862144.
S2CID
257282413.
-
^ Orvain, Cindy; Cauvet, Anne; Prudent, Alexis; Guignabert, Christophe; Thuillet, Raphaël; Ottaviani, Mina; Tu, Ly; Duhalde, Fanny; Nicco, Carole; Batteux, Frédéric; Avouac, Jérôme; Wang, NingXin; Seaberg, Michelle A.; Dillon, Stacey R.; Allanore, Yannick (5 January 2022).
"Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models". Arthritis Research & Therapy. 24 (1): 13.
doi:
10.1186/s13075-021-02709-2.
PMC
8728910.
PMID
34986869.